- Medtronic’s forecast for 2026 adjusted earnings per share (EPS) is between $5.50 and $5.60, falling short of the estimated $5.83.
- The company anticipates organic revenue growth of about 5% for the same period.
- Fourth-quarter adjusted EPS reached $1.62, surpassing both last year’s $1.46 and the estimate of $1.58.
- Total revenue for the quarter was $8.9 billion, a 3.6% increase year-over-year, exceeding the estimate of $8.83 billion.
- Cardiovascular segment revenue rose 6.6% year-over-year to $3.34 billion, beating the estimate of $3.28 billion.
- Revenue from the Medical Surgical segment grew 0.6% year-over-year to $2.21 billion, slightly higher than the estimate of $2.19 billion.
- The Neuroscience segment reported revenue of $2.62 billion, a 2.9% increase, but just shy of the $2.63 billion estimate.
- Diabetes segment revenue saw a 10% year-over-year rise to $728 million, surpassing the expected $706.6 million.
- The adjusted operating margin was 27.8%, higher than the previous year’s 26.9%, but below the estimated 28.5%.
- Medtronic has increased its dividend for Q1 FY26 to $0.71 per share, indicating an annual dividend of $2.84 per share.
- CFO Thierry Piéton commented that the fiscal 2026 guidance reflects a focus on growing revenue through key growth drivers and increased investments, aiming for leveraged operating profit growth before tariffs.
Medtronic Plc on Smartkarma
Analysts on Smartkarma are bullish on Medtronic Plc (MDT US), with insights from renowned researchers like Tina Banerjee and Baptista Research. Tina Banerjee‘s report highlights Medtronic’s submission of the Hugo robotic-assisted surgery system for FDA approval in 2H25, which is anticipated to drive significant growth for the company in the medium-term. With Hugo expected to boost Medtronic’s surgical business in FY26, the company is poised for accelerated growth, particularly in key MedTech markets. The U.S. approval of Hugo further solidifies Medtronic’s growth prospects as a top player in the industry.
On the other hand, Baptista Research underscores a trajectory of sustainable growth for Medtronic with a focus on the successful rollout of the Hugo Robotic Surgical Platform. The company’s recent third-quarter results from fiscal year 2025 reveal promising performance, marked by mid-single-digit organic revenue growth for the ninth consecutive quarter. Key areas of growth such as Cardiac Ablation Solutions, leadless pacing, Neuromodulation, and Diabetes segments have shown strong double-digit improvements, reinforcing Medtronic’s position as a leader in innovative medical technologies.
A look at Medtronic Plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc is positioned with a steady outlook for the long term. Smart karma Smart Scores show that Medtronic scores a 3 on Value, Dividend, Growth, Resilience, and Momentum. This indicates a balanced performance across key factors that impact the company’s prospects. Medtronic, PLC is a developer of therapeutic and diagnostic medical products with a wide-ranging product line that serves various medical needs globally. The scores suggest that while not excelling in any particular area, Medtronic shows consistency and stability across multiple aspects of its operations, which could bode well for its future performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
